Page 155 - rcv31n3.vp

Revista Uruguaya de Cardiología Prevención cardiovascular en el diabético
Volumen 31 | nº 3 | Diciembre 2016 Washington Vignolo, Bernardo Layerle

22. Ranney L, Melvin C, Lux L, McClain E, Lohr Expert Opin Pharmacother. 2010 Jun;11(9):1
KN. Systematic review: smoking cessation interven- 459-66. doi:10.1517/14656561003792538.
tion strategies for adults and adults in special popu-
31. Stavrakis S, Stoner JA, Azar M, Wayangankar
lations. Ann Intern Med. 2006 Dec 5 [citado 2016 Abr
S, Thadani U. Low-dose aspirin for primary preven-
26];145(11):845-56. Disponible en: http://www.
tion of cardiovascular events in patients with diabe-
ncbi.nlm.nih.gov/pubmed/16954352.
tes: a meta-analysis. Am J Med Sci. 2011
23. Nagrebetsky A, Brettell R, Roberts N, Farmer A. Jan;341(1):1-9. doi:10.1097/MAJ.0b013e3181f1fba8.
Smokingcessationinadultswithdiabetes:asystematic
32. De Berardis G, Sacco M, Strippoli GF, Pellegri-
reviewandmeta-analysis of data fromrandomisedcon-
ni F, Graziano G, Tognoni G, et al. Aspirin for
trolled trials. BMJ Open. 2014;4(3):e004107.
primary prevention of cardiovascular events in peo-
doi:10.1136/bmjopen-2013-004107.
ple with diabetes: meta-analysis of randomised con-
24. Park Y, Franchi F, Rollini F, Angiolillo DJ. trolled trials. BMJ. 2009 Nov 6 [citado 2016 Abr
Antithrombotic therapy for secondary prevention in 26];339:b4531. Disponible en: http://www.
patients with diabetes mellitus and coronary artery ncbi.nlm.nih.gov/pubmed/19897665.
disease. Circ J. 2016;80(4):791-801.
33. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M,
doi:10.1253/circj.CJ-16-0208.
et al. Aspirin for primary prevention of cardiovascu-
lar events in patients with diabetes: A meta-analysis.
25. Aspirin effects on mortality and morbidity in pa-
Diabetes Res Clin Pract. 2010 Feb;87(2):211-8.
tients with diabetes mellitus. Early Treatment Dia-
doi:10.1016/j.diabres.2009.09.029.
betic Retinopathy Study report 14. ETDRS Investi-
gators. JAMA. 1992 Set 9 [citado 2016 Abr 34. Buse JB, Ginsberg HN, Bakris GL, Clark NG,
26];268(10):1292-300. Disponible en: http://www. Costa F, Eckel R, et al. Primary prevention of car-
ncbi.nlm.nih.gov/pubmed/1507375. diovascular diseases in people with diabetes mellitus:
a scientific statement from the American Heart Asso-
26. BelchJ,MacCuishA,CampbellI,Cobbe S, Tay-
ciation and the American Diabetes Association. Dia-
lorR,PrescottR,etal. The prevention of progres-
betes Care. 2007 Jan;30(1):162-72.
sion of arterial disease and diabetes (POPADAD) trial:
doi:10.2337/dc07-9917.
factorial randomised placebo controlled trial of aspirin
and antioxidants in patients with diabetes and 35. Pignone M, Alberts MJ, Colwell JA, Cushman
asymptomatic peripheral arterial disease. BMJ. 2008 M, Inzucchi SE, Mukherjee D, et al. Aspirin for
Oct 16 [citado 2016 Abr 26];337:a1840. Disponible en: primary prevention of cardiovascular events in peo-
http://www.ncbi.nlm.nih.gov/pubmed/ 18927173. ple with diabetes:a position statement of the Ameri-
can Diabetes Association, a scientific statement of
27. Ogawa H, Nakayama M, Morimoto T, Uemura
the American Heart Association, and an expert con-
S,Kanauchi M, Doi N, Jinnouchi H, et al; Japa-
sensus document of the American College of Cardio-
nese Primary Prevention of Atherosclerosis
logy Foundation. Circulation. 2010 Jun
with Aspirin for Diabetes (JPAD) Trial Inves-
22;121(24):2694-701. doi:10.1161/CIR.0b013e31-
tigators. Low-dose aspirin for primary prevention of
81e3b133.
atherosclerotic events in patients with type 2 diabe-
tes: a randomized controlled trial. JAMA. 2008 Nov 36. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspi-
12;300(18):2134-41. doi:10.1001/jama.2008.623. rin effect on the incidence of major adverse cardio-
vascular events in patients with diabetes mellitus: a
28. Calvin AD, Aggarwal NR, Murad MH, Shi Q, systematic review and meta-analysis. Cardiovasc
Elamin MB, Geske JB, et al. Aspirin for the pri- Diabetol. 2011 Apr;10(1):25. doi:10.1186/1475-
mary prevention of cardiovascular events: a systema- 2840-10-25.
tic review and meta-analysis comparing patients
with and without diabetes. Diabetes Care. 2009 37. Halvorsen S, Andreotti F, ten Berg JM, Catta-
Dec;32(12):2300-06. doi:10.2337/dc09-1297. neo M, Coccheri S, Marchioli R, et al. Aspirin
therapy in primary cardiovascular disease preven-
29. Antithrombotic Trialists’ (ATT) Collabora- tion: a position paper of the European Society of Car-
tion, Baigent C, Blackwell L, Collins R, Ember- diology working group on thrombosis. J Am Coll Car-
son J, Godwin J, Peto R, et al. Aspirin in the pri- diol. 2014 Jul 22;64(3):319-27. doi:10.1016/
mary and secondary prevention of vascular disease: j.jacc.2014.03.049.
collaborative meta-analysis of individual participant
data from randomised trials. Lancet. 2009 May 38. Piepoli MF, Hoes AW, Agewall S, Albus C, Bro-
30;373(9678):1849-60. tons C, Catapano AL, et al. 2016 European Guide-
doi:10.1016/S0140-6736(09)60503-1. lines on cardiovascular disease prevention in clinical
practice. The Sixth Joint Task Force of the European
30. Younis N, Williams S, Ammori B, Soran H. Role Society of Cardiology and Other Societies on Cardio-
of aspirin in the primary prevention of cardiovascu- vascular Disease Prevention in Clinical Practice
lar disease in diabetes mellitus: a meta-analysis. (constituted by representatives of 10 societies and by
499